ImmunoGen, Inc. (IMGN)
-NasdaqGS 17.89 
0.15(0.85%) May 24, 4:00PM EDT|After Hours
:
17.89 0.00 (0.02%) May 24, 4:35PM EDT
| Prev Close: | 17.74 |
|---|
| Open: | 17.76 |
|---|
| Bid: | 14.49 x 100 |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 14.56 |
|---|
| Beta: | 1.91 |
|---|
| Next Earnings Date: | 2-Aug-13 |
|---|
| Day's Range: | 17.40 - 18.48 |
|---|
| 52wk Range: | 10.85 - 18.48 |
|---|
| Volume: | 1,076,192 |
|---|
| Avg Vol (3m): | 738,261 |
|---|
| Market Cap: | 1.51B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.89 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Angelina Jolie's Selfless Act Heightens Breast Cancer Awarenessat Motley Fool(Wed, May 15)
- Companies Invest in Antibodies That Fight Tumorsat Motley Fool(Mon, May 13)
- ImmunoGen's Management Presents at Credit Suisse Antibody Day Conference (Transcript)at Seeking Alpha(Sat, May 11)
- IMMUNOGEN INC FinancialsEDGAR Online Financials(Fri, May 10)
- ImmunoGen's Symbiotic Relationships Thru TAP Will Beef Up Its Stock Priceat Seeking Alpha(Thu, May 9)
- IMMUNOGEN INC Files SEC form 10-Q, Quarterly ReportEDGAR Online(Mon, May 6)
- Dr. Jason Kantor, Research Analyst at Credit Suisse Group, Interviews with The Wall Street Transcript: High Success Rates and Significant M&A in the Antibody SpaceWall Street Transcript(Fri, May 3)
- ImmunoGen, Inc. Announces Webcast of Presentation at Upcoming Investor ConferenceBusiness Wire(Fri, May 3)
- A Favorable Regulatory Environment for Biotechnology and Pharmaceutical Companies: Senior Analyst Brian Skorney Discusses the Acceleration of FDA Approvals with The Wall Street TranscriptWall Street Transcript(Mon, Apr 29)
- ImmunoGen Narrows LossZacks(Mon, Apr 29)
- 3 Healthcare Stock Winners and 2 Losers After Earnings Are Digestedat Wall St. Cheat Sheet(Sun, Apr 28)
- ImmunoGen's CEO Discusses F3Q 2013 Results - Earnings Call Transcriptat Seeking Alpha(Fri, Apr 26)
- Immunogen Earnings: Here’s Why Investors are Buying Shares Nowat Wall St. Cheat Sheet(Fri, Apr 26)
- Q3 2013 ImmunoGen, Inc. Earnings Release - 06:30 am ETCCBN(Fri, Apr 26)
- ImmunoGen, Inc. Reports Third Quarter Fiscal Year 2013 Financial Results and Provides Quarterly UpdateBusiness Wire(Fri, Apr 26)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 43.27 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Jun-13)
: | -0.93 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.30 |
|---|
| Mean Recommendation*: | 2.4 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
ImmunoGen, Inc. engages in the development of antibody-based anticancer therapeutics. The company develops its products using its targeted antibody payload (TAP) technology.
View More